NAVB Insider Trading Activity and SEC Form 4 Filings
NAVB insider trading summary
No open-market insider purchases or sales of Navidea Biopharmaceuticals, Inc. (NAVB) have been reported on SEC Form 4 in the past 12 months.
Latest NAVB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 10, 2022 | John K Scott Jr. | Director | Buy | $0 (3,260 @ $0.00) |
| Sep 17, 2021 | Malcolm G Witter | Director | Buy | $32K (20,000 @ $1.60) |
| Jul 26, 2021 | Malcolm G Witter | Director | Buy | $25K (15,000 @ $1.70) |
| Apr 23, 2021 | Malcolm G Witter | Director | Buy | $16K (10,000 @ $1.60) |
| Mar 29, 2021 | Malcolm G Witter | Director | Buy | $45K (21,500 @ $2.07) |
| Mar 3, 2021 | Malcolm G Witter | Director | Buy | $35K (15,000 @ $2.31) |
| Dec 28, 2020 | Malcolm G Witter | Director | Buy | $10K (5,000 @ $2.07) |
| Aug 30, 2020 | John K Scott Jr. | 10% Owner | Buy | $25K (5,000 @ $5.00) |
| Feb 20, 2020 | Jed Latkin | CEO, COO & CFO | Buy | $5K (5,000 @ $1.08) |
| Feb 13, 2020 | John K Scott Jr. | 10% Owner | Buy | $2.0M (2,373,529 @ $0.85) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.